The World – Qatar
According to “Qena” agency, the Ministry of Health stated that the agreement provides for the purchase of vaccines from “Moderna”, a specialist in biotechnology and headquartered in Massachusetts, “as soon as these vaccines are approved and prove their suitability for use at the global level.”“.
The head of the national strategy group to address the disease explained ‘COVID-19’ And the head of the infectious diseases department at HMC, Abdul Latif Al-Khal, said that the company “started working on developing and testing a vaccine against the Coronavirus since the beginning of the pandemic“.
Al-Khal added: “The preliminary results of the first and second stages of the important clinical trials conducted by Moderna showed that the bodies of healthy adults have formed antibodies against the Corona virus and have produced immune capabilities to confront this virus through the (T) cells inherent in the human body, while not. Research and experiments are still ongoing and include thousands of volunteers. The informed medical community believes that the preliminary results referred to are encouraging and show remarkable progress in developing a safe and effective vaccine against the virus.“.
Al-Khal, who did not disclose the quantity of doses requested by Qatar: “We continue to work closely with a number of leading pharmaceutical companies in the world who are currently developing vaccines against this disease, and we aim through our efforts to ensure access to vaccines as soon as they are proven effective and effective. Safe to use and approved by the competent international bodies“.
He said, “It was necessary to enter into a number of agreements early, with the aim of increasing the opportunity to obtain adequate quantities of vaccines early.“.
Al-Khal announced earlier this month that Qatar had signed an agreement with the American company “Pfizer” and the German “Biontech” to provide Qatar with vaccines to prevent the disease..
Moderna said last month that it was preparing to produce 20 million doses of its vaccine by the end of the year, while seeking to achieve its goal of producing between 500 million and 1 billion doses in 2021.